Skip to main content

Table 5 Correlations between clinicopathological features and Cyclin D1 expression in all the included cases

From: The values of Transgelin, Stathmin, BCOR and Cyclin-D1 expression in differentiation between Uterine Leiomyosarcoma (ULMS) and Endometrial Stromal Sarcoma (ESS); diagnostic and prognostic implications

CharacteristicsAll (N = 44)Cyclin D1 
  Negative (N = 24)Focal weak +ve (N = 5)Diffuse strong +ve (N = 15)p-value
 No. (%)No. (%)No. (%)No. (%) 
Age (years)
 Mean ± SD56.84 ±7.9362.16 ±4.9151.40 ±11.0150.13 ±3.39<0.001*
 Median (Range)57 (39-72)61.50 (56-72)50 (39-65)50 (44-55) 
 ≤ 55 years18 (40.9%)0 (0%)3 (16.7%)15 (83.3%)<0.001‡
 > 55 years26 (59.1%)24 (92.3%)2 (7.7%)0 (0%) 
Histopathology
 LMS22 (50%)22 (100%)0 (0%)0 (0%)<0.001‡
 ESS22 (50%)2 (9.1%)5 (22.7%)15 (68.2%) 
Grade
 Grade I9 (20.5%)7 (77.8%)2 (22.2%)0 (0%)0.006‡
 Grade II12 (27.3%)7 (58.3%)3 (25%)2 (16.7%) 
 Grade III23 (52.3%)10 (43.5%)0 (0%)13 (56.5%) 
Extrauterine extension
 Absent6 (13.6%)6 (100%)0 (0%)0 (0%)<0.001‡
 Present9 (20.5%)5 (55.6%)4 (44.4%)0 (0%) 
 N/A29 (65.9%)13 (44.8%)1 (3.4%)15 (51.7%) 
LVSI
 Absent21 (47.7%)16 (76.2%)5 (23.8%)0 (0%)<0.001‡
 Present23 (52.3%)8 (34.8%)0 (0%)15 (65.2%) 
Bladder/Rectum extension
 Absent33 (75%)20 (60.6%)4 (12.1%)9 (27.3%)0.017‡
 Present10 (22.7%)4 (40%)0 (0%)6 (60%) 
 N/A1 (2.3%)0 (0%)1 (100%)0 (0%) 
Adnexal invasion
 Absent11 (25%)9 (81.8%)2 (18.2%)0 (0%)0.022‡
 Present33 (75%)15 (45.5%)3 (9.1%)15 (45.5%) 
Lymph node
 Negative16 (36.4%)12 (75%)4 (25%)0 (0%)0.001‡
 Positive28 (63.6%)12 (42.9%)1 (3.6%)15 (53.6%) 
Distant metastasis
 Absent29 (65.9%)20 (69%)5 (17.2%)4 (13.8%)<0.001‡
 Present15 (34.1%)4 (26.7%)0 (0%)11 (73.3%) 
FIGO Stage
 Stage I6 (13.6%)6 (100%)0 (0%)0 (0%)<0.001‡
 Stage II10 (22.7%)6 (60%)4 (40%)0 (0%) 
 Stage III13 (29.5%)8 (61.5%)1 (7.7%)4 (30.8%) 
 Stage IV15 (34.1%)4 (26.7%)0 (0%)11 (73.3%) 
Stathmin
 Negative19 (43.2%)2 (10.5%)5 (26.3%)12 (63.2%)<0.001‡
 Focal weak +ve12 (27.3%)10 (83.3%)0 (0%)2 (16.7%) 
 Diffuse strong +ve13 (29.5%)12 (92.3%)0 (0%)1 (7.7%) 
Transgelin
 Negative25 (56.8%)5 (20%)5 (20%)15 (60%)<0.001‡
 Focal weak +ve6 (13.6%)6 (100%)0 (0%)0 (0%) 
 Diffuse strong +ve13 (29.5%)13 (100%)0 (0%)0 (0%) 
BCOR
 Negative23 (52.3%)21 (91.3%)2 (8.7%)0 (0%)<0.001‡
 Focal weak +ve7 (15.9%)2 (28.6%)3 (42.9%)2 (28.6%) 
 Diffuse strong +ve14 (31.8%)1 (7.1%)0 (0%)13 (92.9%) 
  1. * Kruskal Wallis H test; ‡ Chi-square test; p < 0.05 is significant